Clinical trials: Macular Dystrophy, active
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Neovascular (Wet) Age-Related Macular Degeneration
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual…
- Trial name
- NCT07390253
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Low Vision, Central Visual Impairment
Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss
Central vision loss from macular degeneration creates blind spots that impair reading, face recognition, and navigation. Individuals must learn to use peripheral vision, requiring retraining of eye movements.
- Conditions
- Low Vision, Central Visual Impairment, Macular Degeneration
- Trial name
- NCT07577219
- Testing
- eccentric viewing training with biofeedback
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New England College of Optometry
Age Related Macular Degeneration, Geographic Atrophy
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD.
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy, AMD, Age-related Macular Degeneration
- Trial name
- Project AMD (NCT04739319)
- Testing
- N/A Observational study
- Where
- Australia
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Myopic Traction Maculopathy
Predictors of Vitrectomy Outcomes in Myopic Foveoschisis
This prospective pilot study evaluates factors that predict outcomes after vitrectomy for myopic foveoschisis (MFS), a sight-threatening complication of high myopia that can lead to progressive visual loss, foveal detachment…
- Trial name
- NCT07774637
- Testing
- pars plana vitrectomy
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore National Eye Centre
Age Related Macular Degeneration (AMD)
Development of Novel Clinical Endpoints in Intermediate AMD
Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR
- Trial name
- MACUSTAR (NCT03349801)
- Testing
- No intervention
- Where
- 20 sites in Denmark, France and 5 more
- Volunteers
- 718 people, healthy volunteers welcome
- Sponsor
- Frank G. Holz
Geographic Atrophy, Age - Related Macular Degeneration (AMD)
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2)…
- Trial name
- NCT07705568
- Testing
- PST-611
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Eyevensys
Age-Related Macular Degeneration
Impact of Age-related Macular Degeneration on Daily Living Activitie
The complex and variable course of age-related diseases makes it all the more necessary to carry out personalised, reasoning-based examinations to improve the personalised assessment and management of AMD.
- Trial name
- AMDAY (NCT06333873)
- Testing
- patient-reported outcome
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Age-Related Macular Degeneration (ARMD)
Can the Risk for AMD be Modulated?
The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related…
- Trial name
- AMD_LifeGene (NCT05735730)
- Testing
- Blood draw
- Where
- Portugal
- Volunteers
- 1,800 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
- Trial name
- HANGANG (NCT07461441)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Neovascular Age-related Macular Degeneration
The Sahlgrenska Anti-VEGF Study
The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy…
- Trial name
- SAHLVE (NCT04101877)
- Testing
- Bevacizumab Injection, Aflibercept Injection
- Where
- Sweden
- Volunteers
- 402 people
- Sponsor
- Vastra Gotaland Region
Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Observation of the Natural Course of Age-related Macular Degeneration
This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a…
- Trial name
- NCT05418231
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Macular Degeneration, Age Related
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16. This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of…
- Trial name
- NCT07403825
- Testing
- Vabysmo 6 MG in 0.05 ML Injection
- Where
- 10 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Biobizkaia Health Research Institute
Stage 3 AMD
Lutein by Scleral Iontophoresis in AMD
The objective of the clinical investigation is to evaluate the performance, safety and degree of tolerability resulting from the use of the iontophoresis medical device in adult subjects diagnosed with AMD stage 3 (AREDS…
- Trial name
- NCT06925893
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Federico II University
Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse.
- Conditions
- Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Diabetic Macular Edema (DME)
- Trial name
- IMLADRIS (NCT06914778)
- Testing
- Blood draw for the laboratory assessment, Urine sample
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hywel Dda Health Board
Neovascular Age-related Macular Degeneration
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
- Trial name
- NCT06141460
- Testing
- RRG001
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Refreshgene Technology Co., Ltd.
Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP)
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with…
- Trial name
- RETINA-PRP (NCT07341919)
- Testing
- Subtenon Injection of Autologous Platelet-Rich Plasma
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Rubens Camargo Siqueira